STLN Drops 46% in Snapshot Despite Growth as Guidance Narrows
Starling Oncology sold off after its quarterly update. Examine the mixed guidance changes and why stronger revenue does not settle the stock's valuation.
Read the story
Starling Oncology sold off after its quarterly update. Examine the mixed guidance changes and why stronger revenue does not settle the stock's valuation.
Read the story
CVRx reduced its revenue outlook amid payer and sales-execution problems. Examine the confirmed news, analyst downgrades and risks behind the decline.

AirSculpt lowered its annual outlook after weaker procedure demand. Explore the earnings catalyst, refinancing and risks behind the AIRS selloff.

indie Semiconductor rallied after higher sales and an upbeat revenue outlook. Explore the catalyst, GAAP losses and the next tests for profitability.

Senstar’s quarterly sales and profit supported a sharp SNT rally. Explore the earnings catalyst, margin questions and tests for a lasting improvement.

Clean Energy raised its annual adjusted EBITDA outlook, with higher RNG volumes and tax-credit benefits supporting results. An $8.3 million catch-up complicates the quarterly run rate.

Gogo's loan extension and decade-long spectrum renewal offer concrete catalysts, while Galileo adoption must translate into stronger overall financial results.

SunCar's preliminary nine-month profit forecast and new repurchase authorization provide two concrete catalysts, with cash conversion and buyback execution still to prove.

ThredUp's holiday-quarter revenue forecast missed expectations, putting profitability and analyst downgrades in focus after a sharp selloff.

Teads' weak quarter combines falling revenue, negative adjusted EBITDA and substantial debt; its large noncash impairment must be separated from cash burn.

A revenue miss, weaker outlook and sales-team disruption explain why MNTN's growing earnings failed to reassure investors.

Fluent's growing commerce-media business explains why its next earnings release deserves attention, but losses and financing risk remain central.